Study Summary
The purpose of this study is to describe feasibility of delivering point-of-care manufactured CD19-directed CAR T-cell therapy to patients with relapsed/ refractory B-lineage leukaemia/ lymphoma.
Want to learn more about this trial?
Request More InfoInterventions
Anti-CD19 CAR T-cellsBIOLOGICAL
A target per-protocol dose of vi able CD19 CAR transduced T-cells will consist of a single infusion of 0.2 to 5.0 x 10e6 lentiviral-transduced viable 41BB-CD19 CAR T-cells per kg body weight.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Singapore General Hospital | Singapore | Singapore | |
| KK Women's and Children's Hospital | Singapore | Singapore |